To investigate whether the b 3 -adrenoceptor could be identified by immunohistochemistry in intact human white and brown adipocytes and other human tissues, and to investigate the influence of obesity and its treatment with ephedrine and caffeine on the expression of the b 3 -adrenoceptor in adipocytes. METHODS: Morbidly obese patients were given a hypoenergetic diet (70% of energy expenditure) and some were also treated with ephedrine and caffeine (20=200 mg, three times daily) for 4 weeks. Adipose tissue and other tissues were taken during surgery. Immunohistochemistry was carried out using a monoclonal antibody raised against the human b 3 -adrenoceptor. RESULTS: Staining was localized to the periphery of cells. All white adipocytes were stained. Those from lean subjects and obese subjects treated with ephedrine and caffeine showed more intense staining than those from untreated obese subjects. Staining was more intense in brown than in white adipocytes in perirenal adipose tissue from phaeochromocytoma patients. Staining was also seen in ventricular myocardium, and in smooth muscle of the prostate, ileum, colon and gall bladder. DISCUSSION: The tissue and subcellular distribution of staining was consistent with it being due to binding of the antibody to the human b 3 -adrenoceptor. The presence of the b 3 -adrenoceptor in human white adipocytes is consistent with evidence that it can mediate lipolysis in human white adipocytes. The increased expression of the b 3 -adrenoceptor in obese subjects treated with caffeine and ephedrine supports the potential of b 3 -adrenoceptor agonists in the treatment of obesity and type 2 diabetes. Its expression in ventricular myocardium is consistent with evidence that the b 3 -adrenoceptor mediates a negative inotropic effect in this tissue.
Introduction
Mammalian (including human) adipose tissue is composed mainly of white and brown adipocytes. White adipocytes store lipids in unilocular droplets, whereas brown adipocytes store lipids in multilocular droplets. This reflects the different functions of these two cell types. White adipocytes store lipids and release fatty acids in the intervals between meals to provide other tissues with a source of energy other than glucose. Brown adipocytes, on the other hand, oxidize most of the stored intracellular lipid and release the energy as heat. The oxidation of lipids in brown adipocytes can be very rapid because it is uncoupled from the synthesis of ATP by the mitochondrial uncoupling protein-1 (UCP-1).
of rats with the b 3 -adrenoceptor agonist CL-316243 for 7 days, multilocular adipocytes arose directly from conversion of unilocular white adipocytes. Only a few of these 'convertible' brown adipocytes expressed UCP-1, however. Moreover, only a minority showed the complete differentiation of mitochondria characteristic of brown adipocytes, and some showed morphological features typical of white adipocytes during lipolysis. 4 Lipolysis in white and brown adipocytes is activated by sympathetic stimulation of b-adrenoceptors. In rodents the b 3 -adrenoceptor plays the dominant role in these cells. This partly explains why b 3 -adrenoceptor agonists are highly effective in causing weight loss and improving insulin sensitivity in animal models of obesity and type 2 diabetes: brown adipose tissue (together with skeletal muscle) is an important site of thermogenesis, whilst white adipose tissue provides much of the fuel for thermogenesis. 5 The conversion of unilocular to multilocular adipocytes by repeated administration of b 3 -adrenoceptor agonists is probably part of the mechanism by which the thermogenic effect of b 3 -adrenoceptor agonists increases with time. 6 The role of the b 3 -adrenoceptor in humans is more controversial. No b 3 -adrenoceptor agonist has so far progressed beyond phase II clinical trials for obesity or type 2 diabetes. It is unclear whether this is because a compound with suitable selectivity for the b 3 -adrenoceptor and drug properties (eg oral bioavailability) has not been found, or because the b 3 -adrenoceptor has a lesser role in humans than in rodents. There is some functional evidence for b 3 -adrenoceptors in human white adipocytes, but such evidence is more difficult to obtain than with rodent white adipocytes. b 3 -Adrenoceptor mRNA is expressed in human adipose tissue, but in lower amounts than in rodents. 5 Immunohistochemistry using one antibody has demonstrated the presence of the receptor in gallbladder and in vascular and non-vascular smooth muscle, but not, it seems, in adipose tissue. 7 Another antibody has been used to demonstrate the presence of the receptor in human white adipose membranes using timeresolved fluorescence. It was not possible, however, in that study to identify the receptor in intact adipocytes owing to the difficulty of interpreting labelling of these thin-walled cells. 8 Nevertheless, using this latter antibody, we are now able to show unequivocally using light microscopy that the b 3 -adrenoceptor is present in adipose tissue of lean and obese humans. Furthermore, the receptor was detected on ventricular myocardium, with weak staining detected on smooth muscle cells of the small intestine, gall bladder and prostate.
Patients and methods
Patient selection for white adipose tissue biopsies Morbidly obese patients were selected from the waiting list for bariatric surgery at the Surgical Department, Molinette Hospital, Turin. In order to be admitted for bariatric surgery, they had to have BMI > 40 kg=m 2 , a history of unresponsiveness to previous, medically supervised, weight-reduction therapy, and no major psychiatric illness. Only premenopausal females who were non-smokers or smoking less than five cigarettes per day were selected for the research protocol. Exclusion criteria were: ischaemic heart disease, cardiac insufficiency, hypertension requiring pharmacological treatment, tachyarrhythmias, sick sinus syndrome, AV block, two-bundle ventricular block, cerebrovascular disease, occlusive peripheral artery disease, renal insufficiency and current treatment with drugs that might affect metabolic rate (eg beta-blockers, thyroid hormones).
Patients were randomized to treatment with either caffeine= ephedrine (200=20 mg three times daily) or placebo of identical appearance. Treatment was started 4 weeks before the scheduled date of the operation at an intial dose of a half tablet three times daily for the first week, before proceeding to the full dose of one tablet three times daily. Blood pressure was measured three times a day and an electrocardiogram was recorded weekly, but no cardiovascular side-effects were detected. Three patients (one in the placebo and two in the treatment group) complained of insomnia after the first week and were returned to half dosage for the entire treatment period.
Patients were hospitalized during the whole treatment period, first in a metabolic ward and then for 3 -6 days prior to surgery in the Surgical Department in Turin. Treatment was discontinued on the day before the operation. During the treatment period the patients were put on a hypoenergetic diet of total energy content equal to about 70% of energy expenditure as measured by indirect calorimetry, and containing 20% protein, 55% carbohydrate and 25% fat, of which half was monounsaturates, plus 35 g=day of fibre. Weight loss (expressed as body mass index units) over the 4 weeks of treatment before surgery averaged about 3 kg=m 2 in those patients on the ephedrine=caffeine treatment and about 2 kg=m 2 in those on placebo. Surgery consisted of either gastroplasty or gastric banding via a laparoscopic approach. At the time of laparotomy adipose tissue samples from omental (n ¼ 9) and subcutaneous (n ¼ 14) sites were excised and fixed as described below.
The study included subcutaneous adipose tissue from three lean patients (two men and one woman, 17 -44 y old) undergoing surgery from clinical purposes.
In summary, we studied three lean, six obese untreated and eight obese patients treated with ephedrine and caffeine.
The study protocol was approved by the Ethical Committee of the Istituto Auxologico Italiano and by the Regional Ethical Committee of Piedmont. All patients were required to sign a written consent form.
Other tissue biopsies Specimens of prostate (n ¼ 4), gall bladder (n ¼ 1), small intestine (ileum; n ¼ 2), large intestine (colon; n ¼ 2), skeletal muscle (m. soleus and m. pectoralis; n ¼ 3), bladder (n ¼ 2) Perirenal adipose tissue from phaeochromocytoma patients (n ¼ 4) and ventricular biopsies (n ¼ 11) were collected from the Anatomy Pathology Institute, 'Casa Sollievo della Sofferenza' Hospital, S. Giovanni Rotondo, Italy.
Right ventricular myocardial biopsies (n ¼ 9) were obtained from patients (seven men and two women, 20 -50 y old), of whom four had dilatative cardiomyopathy, two had arrhythmogenic cardiomyopathy, one had ischaemic cardiomyopathy, one had restrictive cardiomyopathy and one studied for a suspected arrhythmogenic displeasure that was found to be 'normal' after histological examination. Autoptic left ventricular myocardium (n ¼ 2) was also studied.
Informed consent was obtained from the patients or their relatives. None of the patients, except those with phaeochromocytoma, had diseases known to interfere with the b-adrenergic system.
Microscopy
Tissues were fixed by immersion in 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. After washing in this buffer overnight, the samples were dehydrated in a graded series of ethanol solutions and embedded in paraffin blocks ready for light microscopy. For immunohistochemistry 10 mm (white adipose tissue) or 3 mm sections (other tissues) were immunostained by the avidin-biotin peroxidase (ABC) technique. 9 Dewaxed sections were processed through the following steps: (1) hydrogen peroxide (0.3%) in methanol for 30 min to block endogenous peroxide; (2) normal rabbit serum (1:75) for 20 min to reduce non-specific background staining; (3) monoclonal anti-human b 3 -adrenoceptor antibody Hydrated sections of perirenal adipose tissue from phaeochromocytoma patients were processed for UCP1 primary antibody, (generously provided by Dr D Ricquier, Meudon, France; diluted 1:10 000) and labelled with the ABC method as described above using normal rabbit serum and biotinylated rabbit anti-sheep IgG.
Results
All the white adipocytes from subcutaneous and omental depots were b 3 -adrenoceptor-immunoreactive (Figure 1) . Staining at the peripheral cytoplasmic rim was clearly evident in adipocytes from both lean (Figure 1a) and Paraffin embedded tissues, ABC method. All images were taken by a digital camera Nikon-DXM 1200 (Nikon Europe BV, The Netherlands), mounted on a Nikon-Eclipse E800 Microscope (Nikon Europe BV, The Netherlands) at the same enlargment (20Â) and using the same light filter and the same intensity of luminosity. In both unilocular white and multilocular brown adipocytes are visible. Both resulted b 3 adrenoceptor immunoreactive in their cytoplasm (a and c). Some brown adipocytes appear more intensely stained than others (arrows). Brown adipocytes located in the same region of the tissue were also UCP1 stained (b and d). Some of them resulted more intensely stained (arrows). Bar: (a) (Figure 1c ) subjects, but was more intense in adipocytes from the lean subjects. No staining was seen when the primary antibody was omitted (Figure 1b) . Adipocytes from obese patients treated with caffeine and ephedrine (Figure 1d ) showed more intense staining than adipocytes from placebo-treated obese subjects (Figure 1c) , and comparable staining to that of lean subjects (Figure 1a) .
Several clusters of brown adipocytes in between white adipocytes were observed in the perirenal adipose tissue of phaeochromocytoma patients. In these samples both white and especially brown adipocytes were b 3 -adrenoceptorimmunoreactive (Figure 2a and c) . The intensity of staining of brown adipocytes varied greatly from cell to cell (Figure 2a) .The samples analysed for b 3 -adrenoceptor were processed with anti-UCP1 antibodies. Some multilocular adipocytes also express UCP1 (Figure 2b and d) .
Immunoreactivity was also detected in ventricular myocardial cells. Figure 3a shows strong staining in myocardium from a 'normal' living patient; not all the myocardial cells were stained. Endothelial cells and smooth muscle fibres in the wall of the vessels were negative. The immunoreactivity was weaker in one of the two samples from autopsies (left ventriculum) and in seven of the nine biopsies from living patients (right ventriculum; Figure 3c ). The enlargement of Figure 3d shows that the immunoreactivity was often localised to the periphery of the cells.
We found positive staining in several other tissues: prostate, intestine and gall bladder (Figure 4 ). In the prostate only stromal smooth muscle cells were immunoreactive, but the intensity of the staining was highly variable (Figure 4a ). Weaker staining was present in smooth muscle cells of the lamina propria of the gall bladder (Figure 4c ) and the ileum and colon (not shown). (Figure 4d ) of all the patients were unstained, as were the smooth muscle fibres of the wall of the arterioles and veins present in all organs examined (adipose tissue, intestine, bladder, prostate, gall bladder, lung).
Discussion
It is well established that b 3 -adrenoceptor mRNA is expressed in rodent adipocytes and that b 3 -adrenoceptors play a functional role. The existence and role of b 3 -adrenoceptors in human adipocytes is more controversial, however. Most, 10 -14 although not all 15, 16 workers have detected b 3 -adrenoceptor mRNA in human adipose tissue, but expression is some 50-fold lower than in rodent adipose tissue 13, 14 and b 3 -adrenoceptor transcripts represent less than 20% of total b-adrenoceptor transcripts compared with more than 90% in rodents. 12 Studies in transgenic mice indicate that the promoter for the human b 3 -adrenoceptor drives expression mainly in brown adipose tissue, of which there is relatively little in adult humans. 17 Functional evidence for b 3 -adrenoceptors in white adipocytes was largely based upon the lipolytic activity of CGP-12177, which was believed to be a potent b 1=2 -adrenoceptor antagonist and a b 3 -adrenoceptor agonist at somewhat higher concentrations. CGP-12177 has now, however, been shown also to activate a conformation of the b 1 -adrenoceptor (previously called the b 4 -adrenoceptor). 18, 19 The activation of b 1 -adrenoceptors by CGP-12177 is less sensitive than activation by standard agonists to b 1 -adrenoceptor antagonists. The pharmacology of the b 1 -adrenoceptor when stimulated by CGP-12177 therefore resembles that of the b 3 -adrenoceptor. Nevertheless, there are selective b 3 -adrenoceptor agonists (SB-226552; SB-251023) which do not activate b 1 -(or 'b 4 -') adrenoceptors and which stimulate lipolysis in human white adipocytes. 19 -21 Thus the low In the present study we provide direct evidence for the existence of b 3 -adrenoceptor protein in white adipocytes from both lean and obese subjects and in brown adipocytes from phaeochromocytoma patients using immunohistochemistry coupled with light microscopy. A previous study demonstrated the selectivity of the antibody that we have used for the human cloned b 3 -adrenoceptor over b 1 -and b 2 -adrenoceptors, and detected the b 3 -adrenoceptor in adipocyte membranes by time-resolved fluorescence. 8 The authors were unable, however, to detect the b 3 -adrenoceptor in intact adipocytes. Our success in this respect may be due to our experience in fixing and embedding adipose tissue samples. 22 We also demonstrate the presence of the b 3 -adrenoceptor in some other human tissues, notably myocardium.
Staining was often localized to the periphery of cells (eg Figure 3d) , as would be expected of a 7-transmembrane receptor. Moreover, the tissue distribution of immunoreactivity stongly supports the evidence of the previous paper. 8 that the antibody selectively detects the b 3 -adrenoceptor rather than b 1 -or b 2 -adrenoceptors. First, no immunoreactivity was detected in lung, skeletal muscle or arterioles, which are known to express high numbers of b 2 -adrenoceptors. Secondly, staining of cardiac tissues and intestine was far less pronounced than would be expected of an antibody that reacts with b 1 -adrenoceptors. Thirdly, staining was especially pronounced in multilocular adipocytes of perirenal tissue from phaeochromocytoma patients, consistent with the higher expression of b 3 -adrenoceptor mRNA in brown compared to white adipocytes. 10, 16 In contrast, expression of the b 1 -adrenoceptor is lower in brown than in white adipocytes, at least during the transformation of bovine perirenal adipose tissue from brown into white fat. 23 Lastly, staining was less in obese than in lean subjects but was restored to the level in lean subjects by treatment with ephedrine and caffeine. Since ephedrine promotes noradrenaline release as well as causing some direct stimulation of adrenoceptors, and with caffeine it enhances sympathetic activity, it is to be expected that it would have a similar effect to phaeochromocytoma on b 3 -adrenoceptor expression. Indeed there is evidence that the thermogenic effect of ephedrine in humans is in part mediated by b 3 -adrenoceptors 24 and that the b 3 -adrenoceptor-mediated component of this effect is enhanced by repeated administration of ephedrine or ephedrine plus caffeine. 25, 26 This latter finding also accords with the expectation that the thermogenic response to a b 3 -adrenoceptor agonist should increase during chronic therapy, at least in part because it leads to increases in brown adipocyte and therefore b 3 -adrenoceptor numbers. Indeed, clinical data from the obese subjects of the present study on body composition, resting energy expenditure and lipid metabolism are overall compatible with a more pronounced thermogenic and lipolytic effect by ephedrine plus caffeine plus energy restriction as compared to energy restriction alone (manuscript in preparation).
The role of the b 3 -adrenoceptor in the human heart, like that in human white adipose tissue, is unclear (see Gauthier et al 27 for review). Some workers have detected b 3 -adrenoceptor mRNA in human atrium and some in ventricle. 10, 11, 28 There is, however, no evidence that the b 3 -adrenoceptor mediates a functional response in human atrium. The work of Kaumann and colleagues demonstrated the presence of a b 4 -adrenoceptor-mediated positive inotropic response in human atrium, but the b 4 -adrenoceptor is now believed to be a form of the b 1 -adrenoceptor. 29 b 3 -Adrenoceptor agonists that have no effect at the b 1 -adrenoceptor were ineffective in human atrium. 20 In contrast, Gauthier, Balligand and colleagues have described a b 3 -adrenoceptor-mediated response in human ventricle, but surprisingly this is an inhibition rather than stimulation of contraction, 27 emphasizing the potential of b 3 -adrenoceptor agonists to stimulate metabolic rate without increasing heart rate in humans.
The present study shows that b 3 -adrenoceptor immunoreactivity is present in human ventricle. The same antibody has been used previously to detect the b 3 -adrenoceptor in left ventricular myocytes, 30 but the first study using this antibody detected the b 3 -adrenoceptor in human atrium but not ventricle. 8 The balance of evidence is nevertheless that the b 3 -adrenoceptor is present in human ventricle where it mediates a negative inotropic response.
Our finding of b 3 -adrenoceptor immunoreactivity in intestine agrees with work using a different antibody 31 and is consistent with evidence that b 3 -adrenoceptor mRNA is expressed in human small intestine. 11, 14 Functional evidence for b 3 -adrenoceptors in the human gastrointestinal tract is restricted to work with colon tissue. The finding of immunoreactivity in gall bladder and prostate is also consistent with previous work. 8,10,11,32 -34 We did not detect b 3 -adrenoceptor immunoreactivity in human skeletal muscle. b 3 -Adrenoceptor expression in skelatal muscle remains controversial. Skeletal muscle appears to be a site of b 3 -adrenoceptor-stimulated thermogenesis, 35 functional studies suggest that the receptor is present in rat soleus muscle, 36 and previous work with the same antibody did detect b 3 -adrenoceptor immunoreactivity in a proportion of human myofibrils in two out of three samples of gastrocnemius muscle. 8 These discrepancies may reflect an irregular b 3 -adrenoceptor distribution in the sites from which skeletal muscle was obtained. Differences in b-adrenoceptor density among muscle fibre types have been described previously. 37 In conclusion, we have detected the b 3 -adrenoceptor by immunohistochemistry in intact human adipocytes. The receptor was more abundant in multilocular than in unilocular adipocytes. Its abundance was lower in adipocytes from obese than from lean subjects, but therapy with ephedrine and caffeine increased expression in the obese subjects. 
